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OBJECTIVES The aim of the study was to test the hypothesis that angiotensin II (Ang II) blockade would
improve exercise tolerance in patients with diastolic dysfunction and a marked increase in
systolic blood pressure (SBP) during exercise.
BACKGROUND Diastolic dysfunction may be exacerbated during exercise, especially if there is a marked
increase in SBP. Angiotensin II may contribute to the hypertensive response to exercise and
impair diastolic performance.
METHODS We performed a randomized, double-blind, placebo-controlled, crossover study of two weeks
of losartan (50 mg q.d.) on exercise tolerance and quality of life. The subjects were 20 patients,
mean age 64 6 10 years with normal left ventricular systolic function (EF .50%), no
ischemia on stress echocardiogram, mitral flow velocity E/A ,1, normal resting SBP
(,150 mm Hg), and a hypertensive response to exercise (SBP .200 mm Hg). Exercise
echocardiograms (Modified Bruce Protocol) and the Minnesota Living With Heart Failure
questionnaire were administered at baseline, and after each two-week treatment period,
separated by a two-week washout period.
RESULTS Resting blood pressure (BP) was unaltered by placebo or losartan. During control, patients
were able to exercise for 11.3 6 2.5 (mean 6 SD) min, with a peak exercise SBP of 226 6
24 mm Hg. After two weeks of losartan, baseline BP was unaltered, but peak SBP during
exercise decreased to 193 6 27 mm Hg (p , 0.05 vs. baseline and placebo), and exercise time
increased to 12.3 6 2.6 min (p , 0.05 vs. baseline and placebo). With placebo, there was no
improvement in exercise duration (11.0 6 2.0 min) or peak exercise SBP (217 6 26 mm Hg).
Quality of life improved with losartan (18 6 22, p , 0.05) compared to placebo (22 6 26).
CONCLUSIONS In patients with Doppler evidence of diastolic dysfunction at rest and a hypertensive response
to exercise, Ang II receptor blockade blunts the hypertensive response to exercise, increases
exercise tolerance and improves quality of life. (J Am Coll Cardiol 1999;33:1567–72) © 1999
by the American College of Cardiology
Many elderly subjects and patients with hypertension or left
ventricular (LV) hypertrophy have Doppler echocardio-
graphic evidence of impaired diastolic function, but do not
have any symptoms of heart failure at rest (1–3). The ability
to increase the cardiac output during exercise without an
abnormal elevation in left atrial pressure depends on the
capacity of the left ventricle to enhance its diastolic filling
(4). Thus, it is likely that diastolic dysfunction may limit
exercise tolerance before resulting in symptoms at rest.
Elevated systolic arterial blood pressure (BP) impairs
diastolic performance. This is dramatically apparent in
patients who develop flash pulmonary edema in associa-
tion with a marked increase in systolic BP (SBP)
(.200 mm Hg) (5). Lowering the arterial pressure produces
a rapid resolution of the pulmonary edema. Systolic arterial
pressure normally increases during exercise. In elderly and
hypertensive subjects the increase in systolic arterial pressure
during exercise is frequently exaggerated (6 – 8). The
exercise-induced increase in systolic arterial pressure may be
partially mediated by angiotensin II (Ang II), whose circu-
lating levels increase during exercise (9). Furthermore, Ang
II impairs LV relaxation (10). This effect may be accentu-
ated in the failing heart and also in hypertrophied myocar-
dium (10–12). These observations suggest that blocking the
generation or action of Ang II could improve diastolic
function during exertion, thus enhancing exercise tolerance.
Accordingly, we performed a randomized, double-blind,
placebo-controlled, crossover study of the Ang II receptor
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blocker, losartan, on exercise tolerance and quality of life in
patients with Doppler-echocardiographic evidence of mildly
impaired diastolic performance and a marked hypertensive
response to exercise.
METHODS
Patient population. Twenty-one subjects were recruited
from patients undergoing exercise testing for the evaluation
of coronary artery disease as the cause of exertional dyspnea.
Entry criteria included left ventricular ejection fraction
.50% by 2-D echocardiography, no evidence of myocardial
ischemia on stress echocardiogram, no valvular heart dis-
ease, resting SBP #150 mm Hg, mitral valve Doppler flow
pattern with peak E wave less than peak A wave velocity
(E/A ,1.0), and peak SBP .200 mm Hg during exercise.
Patients taking an Ang II receptor blocker were excluded,
whereas patients taking other medications were not ex-
cluded. Patients with other diseases that could limit exercise
tolerance were excluded.
Protocol. Each subject provided informed, written consent
to the protocol that had been approved by our institutional
review board. All baseline medications were continued
during the study. Baseline serum electrolytes, resting 2-D
echocardiogram, and Doppler measurements of mitral valve
flow velocities were obtained. The subjects completed the
Minnesota Living With Heart Failure questionnaire (13),
modified to assess symptoms over the preceding two weeks.
The subjects then underwent a baseline treadmill exercise
test using the modified Bruce Protocol (14). Blood pressure
was obtained using a sphygomanometer at the end of each
3-min stage. Immediately after exercise the Doppler-
echocardiogram was repeated. The patients were randomly
assigned to receive placebo or 50 mg of losartan in identical
gelatin capsules each morning upon awakening. Both inves-
tigators and the subjects were unaware of the assignment.
After two weeks, the treadmill exercise test and baseline
studies were repeated 2 to 4 h after taking the study
medication. Then the study medication was discontinued
for two weeks, and the patients then crossed over to placebo
or losartan. After two weeks of therapy, the studies were
repeated.
Echocardiogram. Resting LV volumes and ejection frac-
tion were measured from the apical four-chamber view
using the modified Simpson’s rule method (15). Left ven-
tricular mass was calculated using the area length method
(15). The transmitral flow velocity was measured using
pulsed-wave Doppler with the sample volume positioned
between the mitral leaflet tips during diastole (16). The E
wave and A wave peak velocities, the ratio of the E wave to
A wave peak velocities (E/A ratio), E wave deceleration
time, and the isovolumetric relaxation time (IVRT) were
measured on three separate beats and then averaged. The
transmitral Doppler measurements were measured at rest
and immediately postexercise.
Statistical analysis. Data are expressed as mean 6 SD.
Analysis of variance of repeated measures was used to
compare the initial control, placebo and losartan values.
Between-group comparisons were performed using the
Tukey test. The level of significance was taken as p , 0.05.
Because the Minnesota Living With Heart Failure score is
not normally distributed, the placebo and losartan scores
were compared using the Wilcoxin signed rank-sum test
(17).
RESULTS
Patient characteristics. Twenty-one patients entered the
study. One patient experienced an increase in serum creat-
inine from 1.5 to 2.0 mg/dl while receiving the initial study
medication (losartan). The patient was withdrawn from the
study. No other subject developed any abnormality of serum
electrolytes or creatinine. Twenty patients completed the
study: 4 men and 16 women. The mean age was 64 6 10
years (range 53 to 79 years). Sixteen patients had a past
history of hypertension but had resting SBP #150 mm Hg
on medications at the time of entry into the study (Table 1).
Seven patients were taking beta-blockers, six were taking
diuretics, five were taking calcium blockers, and six were
taking angiotensin-converting enzyme (ACE) inhibitors.
Resting BP was well controlled (143/79 6 8/8 mm Hg) at
baseline. The patients exercised for 11 6 2.5 min on the
initial exercise test, stopping because of dyspnea or fatigue.
No patient experienced angina. The peak SBP during
exercise was 226 6 24 mm Hg and was greater than
200 mm Hg in all patients (an entry criteria).
Baseline Doppler echocardiographic results. The resting
LV end-diastolic volume was 87 6 26 ml, the LV end-
systolic volume was 36 6 16 ml, the ejection fraction was
0.60 6 0.10, and the LV mass was 90 6 26 gm/m2. Five
patients had LV hypertrophy (LV mass .110 gm/m2). The
resting mitral valve E/A ratio was 0.75 6 0.13 and less than
1.0 in all subjects (an entry criteria). The E/A ratio
increased after exercise to 0.91 6 0.19 ms (p , 0.05) and
the E deceleration time decreased from 197 6 31 ms to
172 6 30 ms (p , 0.05) (Table 2).
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
Ang II 5 angiotensin II
BP 5 blood pressure
IVRT 5 isovolumetric relaxation time
LV 5 left ventricular
SBP 5 systolic blood pressure
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Effect of placebo and losartan in exercise parameters.
The resting systolic and diastolic pressures were unaltered
by placebo or losartan compared with control (Table 3; Fig.
1). The exercise time was similar during baseline (11.3 6
2.5 min) and placebo (11.0 6 2.0) but significantly (p ,
0.05) increased during losartan (12.3 6 2.6 min). In 16 of
the 20 patients, exercise time was longer on losartan than
placebo, in two patients it was identical, and in two others
exercise time was longer on placebo by one min. Both
systolic and diastolic BP readings at rest were not altered by
losartan or placebo. However, peak SBP during exercise was
reduced on losartan to 193 6 27 mm Hg compared to
placebo (217 6 26, p , 0.05) and baseline (226 6
24 mm Hg, p 5 NS). Similarly, the exercise time required
to achieve a SBP .190 mm Hg was delayed on losartan to
10.6 6 3.3 min compared to placebo (8.7 6 3.5 min, p ,
0.05), which was similar to baseline (7.5 6 3.3). Peak heart
rate was unaffected by losartan. Quality of life assessed by
the modified Minnesota Living With Heart Failure score
improved to 18 6 22 on losartan compared with placebo
(22 6 26, p , 0.05), which was similar to baseline (25 6
22). Similarly, using only the questions directly assessing
exercise tolerance, the score improved on losartan (5.2 6
7.3) compared to placebo (9.9 6 7.7, p , 0.05), which was
similar to control (9.9 6 7.9).
Neither losartan nor placebo had any significant effect on
LV end-diastolic volume, IVRT, mitral E/A ratio, or
E-wave deceleration (Table 4). They also had no effect on
resting SBP or heart rate.
DISCUSSION
We studied patients with diastolic dysfunction manifested
by an altered Doppler-echocardiographic pattern of LV
filling with a reduced mitral valve E wave and enhanced A
wave. This “impaired relaxation pattern” of LV filling is an
early manifestation of abnormal LV diastolic performance
(2,3). In our subjects, the abnormal LV filling pattern
resulted from hypertension, LV hypertrophy, or the normal
aging process (18). The patients had normal LV ejection
fractions, and none of the patients had evidence of exercise-
induced myocardial ischemia. All of our patients were
asymptomatic at rest but had dyspnea with exertion. After
exercise the mitral valve E/A ratio increased, and the E wave
deceleration time shortened. These changes are consistent
with an increase in left atrial pressure (19). Such an increase
in left atrial pressure with exercise may have contributed to
the patients’ exertional dyspnea. The addition of an angio-
tensin AT1-receptor blocker, losartan, to the patients’ med-
ications improved our subjects’ ability to walk on a treadmill
by approximately 1 min using the Modified Bruce Protocol.
The improvement in treadmill exercise time was also man-
ifest as an increase in quality of life and exercise tolerance as
measured by the Minnesota Living With Heart Failure
questionnaire (13). These improvements occurred despite
Table 1. Patient Characteristics
Patient Gender/Age (yrs)
Systolic BP
Exercise Time
(min)
Medications
Rest
(mm Hg)
Exercise
(mm Hg)
Beta-
Blocker Diuretic
Calcium-
Blocker ACE-I
1 F/69 142 264 9
2 F/62 148 224 12 x
3 F/75 148 226 9.5 x x
4 F/42 130 224 12 x
5 M/70 150 212 14 x
6 F/70 142 264 13 x
7 F/79 150 206 14 x x
8 F/47 150 208 11 x
9 F/60 140 286 10 x x
10 F/72 140 244 8 x x
11 F/71 148 236 11
12 F/62 150 210 13 x
13 F/51 140 202 14 x x
14 M/58 128 208 13 x
15 F/69 146 206 12 x
16 M/70 150 222 7 x x
17 F/75 142 210 8 x x
18 M/53 140 218 14 x
19 F/57 120 244 15
20 F/70 150 204 7 x
Mean 64 143 226 11
SD 10.1 8.4 24 2.5
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relatively good exercise tolerance (11.3 6 2.5 min), mild
symptoms and normal SBP at baseline.
Mechanism. What is the mechanism of the losartan-
induced improvement of exercise tolerance in our study?
Two weeks of losartan therapy did not alter any Doppler-
echocardiographic measure of LV diastolic performance
(mitral E/A, IVRT or deceleration time) at rest. Thus, a
change in the baseline diastolic function is not the mecha-
nism of losartan’s action. However, a longer course of
therapy might have produced improvement in diastolic
function by inducing regression in patients with LV hyper-
trophy.
Despite well-controlled BP at rest, our patients had an
increase in SBP to .200 mm Hg during exercise prior to
treatment with losartan. Such systolic hypertension during
exercise is common (perhaps typical) in subjects over 60 and
occurs in many patients with hypertension even when BP is
well controlled at rest (6,8). An increase in arterial systolic
pressure increases LV afterload, thus slowing LV relaxation
and reducing the extent of ejection. The ventricle operates
at higher volumes (utilization of preload) and there is an
increase in left atrial pressure in response to increased
systolic load (20). Although losartan did not reduce resting
BP, it slowed the increase in SBP during exercise and
decreased the peak SBP by a mean of 33 mm Hg. It is likely
that the decrease of SBP during exercise contributed to the
improvement in exercise tolerance with losartan. Our find-
ings also demonstrate the role of Ang II acting through AT1
receptors, in contributing to the increase in SBP during
exercise. Although our patients did not have clinical evi-
dence of exercise-induced myocardial ischemia, it is possible
that losartan improved endothelial function, allowing for
improved coronary perfusion.
Angiotensin II slows the rate of LV relaxation and
increases LV diastolic pressures (10). Thus, some of the
beneficial effect of losartan in our study may have been due
to blocking the effect of Ang II on LV relaxation during
exercise. Because ACE inhibitors do not prevent the in-
crease in circulating Ang II that occurs during exercise (9),
it is possible that ACE inhibition may not produce the same
Table 2. Baseline Doppler Echocardiographic Characteristics
Patient
Mitral Valve
E/A
E Deceleration
Time LV Volumes
Rest Exercise
Rest
(ms)
Exercise
(ms)
End-Diastolic
(ml)
End-Systolic
(ml)
Ejection
Fraction
LV Mass
(g/m2)
1 0.51 — 255 — 88 43 0.51 73
2 0.98 0.98 175 205 111 44 0.60 61
3 0.74 1.23 220 115 50 15 0.70 135
4 0.75 0.90 200 170 129 54 0.58 58
5 0.67 1.05 195 185 105 30 0.71 85
6 0.79 0.73 210 172 85 40 0.53 58
7 0.83 0.92 186 225 37 5 0.86 75
8 0.81 0.83 165 213 97 42 0.57 69
9 0.85 0.94 205 215 94 44 0.53 90
10 0.88 0.88 170 144 55 13 0.76 73
11 0.77 0.91 155 165 52 17 0.67 97
12 0.92 1.04 170 145 68 34 0.50 69
13 0.54 0.60 160 — 125 61 0.51 127
14 0.68 0.78 175 165 114 56 0.51 86
15 0.65 0.85 168 140 70 31 0.56 133
16 0.52 1.48 205 135 101 46 0.54 117
17 0.63 0.75 260 150 100 44 0.56 132
18 0.73 0.78 200 185 103 48 0.53 97
19 0.86 0.87 230 190 81 30 0.63 68
20 0.81 0.83 240 184 83 32 0.61 92
Mean 0.75 0.91* 197 172* 87 36 0.60 90
SD 0.13 0.19 31 30 26 16 0.10 26
*p , 0.05 vs. rest.
Table 3. Effect of Placebo and Losartan on Exercise Parameters
Baseline Placebo Losartan
Exercise time (min) 11.3 6 2.5 11.0 6 2.0 12.3 6 2.6*†
Resting systolic BP 143 6 8 140 6 21 138 6 14
Resting diastolic BP 79 6 8 77 6 7 76 6 7
Peak systolic BP (mm Hg) 226 6 24 217 6 26 193 6 27*†
Time to BP .190 (min) 7.5 6 3.3 8.7 6 3.5 10.6 6 3.3*†
Heart rate (BPM) 141 6 15 139 6 20 135 6 20
Minnesota Living With
Heart Failure Score
25 6 22 22 6 26 18 6 22*
*p , 0.05 (Placebo vs. Losartan). †p , 0.05 (Losartan vs. Baseline). Values are
mean 6 SD.
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beneficial effects seen with an Ang II receptor blocker in our
study.
Comparison to previous studies. There are few studies of
therapy of diastolic dysfunction to compare to our results.
Similar to our observations with two weeks of losartan
therapy, Setaro et al. (21) found that five weeks of therapy
with the calcium channel blocker verapamil improved tread-
mill exercise time in patients with symptomatic heart failure
and normal LV ejection fractions. The effect of verapamil
on SBP during exercise was not measured. Similarly, short-
term verapamil therapy increased exercise tolerance in pa-
tients with diastolic dysfunction due to hypertrophic car-
diomyopathy (22). However, the effects of losartan and
verapamil in these studies cannot be directly compared
owing to the different selection criteria used. Furthermore,
the effect of long-term therapy of diastolic dysfunction has
not been assessed.
On the basis of isolated anecdotal experience, it has been
suggested that ACE inhibitors should be avoided in elderly
patients with diastolic dysfunction because of hypertensive
LV hypertrophy (23). Our observations demonstrate that
Ang II receptor blocker with losartan was well tolerated and
improved exercise tolerance and quality of life in the
patients in our study, many of whom were elderly, some
with LV hypertrophy.
Study limitations. We measured exercise tolerance using
the Modified Bruce Protocol of treadmill exercise (14). The
duration of exercise in our study may have been influenced
by the patients’ motivation and subjective interpretation of
their symptoms during exercise. These confounding effects
should have reduced our ability to observe a benefit from
losartan therapy. Alternatively, the lower SBP during losar-
tan exercise may have influenced the examiner to push the
subject further. However, exercise tolerance assessed by the
quality of life questionnaire also improved with losartan.
Sixteen of the patients in our study were taking a variety
of common antihypertensive medications, including beta-
adrenergic blocking agents, ACE inhibitors, and calcium
channel blockers. These medications were continued during
the study. Thus, the benefit we observed with losartan
occurred in addition to any beneficial effects of these other
medications. It is also possible that some of the beneficial
effect was due to an interaction of losartan and the baseline
medications that were continued throughout the study.
Although the patients’ mean BP was 143/79 mm Hg at rest
on their baseline medication and not reduced further at rest
by the addition of losartan, it is possible that more aggres-
sive antihypertensive therapy with agents other than an Ang
II receptor blocker could have produced a similar improve-
ment in exercise tolerance.
Several other potential limitations should be considered.
We studied the effect of two weeks of therapy. Thus, it is
possible that the beneficial effects of losartan would not
persist with a longer duration of therapy. A two-week
washout period was used. Although the washout period
exceeds the half-life of losartan (2.1 h) and its active
metabolite (6.3 h) by more than 50-fold (24), we cannot
Table 4. Effect of Losartan on Echo-Doppler Measures of
Diastolic Performance
Baseline Placebo Losartan
Mitral E/A 0.75 6 0.13 0.87 6 0.22 0.85 6 0.14
E Deceleration
Time (ms)
197 6 31 186 6 47 205 6 35
IVRT (ms) 89 6 22 79 6 19 81 6 17
LV EF 62 6 9.3 60.3 6 10 68.9 6 10.1
LV EDV (ml) 87.4 6 25.6 91.8 6 36.1 81.9 6 22.4
Values are mean 6 SD.
Figure 1. Plot of exercise duration (A) and peak systolic blood
pressure (BP) (B) during baseline and during treatment with
placebo and losartan. Treatment with losartan increased exercise
time and reduced peak systolic BP during exercise compared to
baseline and placebo.
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exclude a lingering effect in those patients that received
losartan first. Finally, the large majority (16 of 20) of our
subjects were women. This may result from a higher
prevalence of diastolic dysfunction in women (25).
Conclusions. We found in patients with Doppler-
echocardiographic evidence of mild LV diastolic dysfunc-
tion and a marked hypertensive response to exercise that
treatment with an Ang II receptor blocker blunted the
increase in systolic BP with exercise, improved exercise
tolerance and enhanced the quality of life.
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